Stelara injection for the treatment of moderately to severely active ulcerative colitis in children aged 2 years and older, expanding the drug's use for both major forms of pediatric IBD. The decision follows the FDA's approval of Stelara (ustekinumab, Janssen) in April for children aged 2 years and older with Crohn's disease.
Stelara injection for the treatment of moderately to severely active ulcerative colitis in children aged 2 years and older, expanding the drug's use for both major forms of pediatric IBD.
The decision follows the FDA's approval of Stelara (ustekinumab, Janssen) in April for children aged 2 years and older with Crohn's disease.
Ustekinumab is the first non-TNF-targeting monoclonal antibody to be approved for both pediatric CD and UC.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Stelara injection for the treatment of moderately to severely active ulcerative colitis in children aged 2 years and older, expanding the drug's use for both major forms of pediatric IBD. The decision follows the FDA's approval of Stelara (ustekinumab, Janssen) in April for children aged 2 years and older with Crohn's disease. Ustekinumab is the first non-TNF-targeting monoclonal antibody to be approved for both pediatric CD and UC.
Open the app view to save this story, compare related coverage, and continue from the same source.